Abstract

The methods of bio-control have diversified resulting in study of new fighting measures.  Studies on Euphorbia cyparissias active compounds as well as their in vivo and in vitroactivity revealed a significant pharmacologic activity, encouraging design of a complex original conditioning. Encapsulation techniques can be of considerable help in this endeavour, being a means to protect sensitive active components (such plant’s active compounds) from the environment and from other excipients used. The aim of the present study was to evaluate E. cyparissias extracts inclusion in β-cyclodextrine complexes and thermo gravimetric (TG-DTG) analysing of Euphorbia’s extracts complexes, as a GMP pharmaceutic step, in the study of thermal behaviour of a future finite conditioning destined to demodectic mange treatment, a zoonotic ectoparasitic disease. TG-DTG analysis of pure β-cyclodextrine revealed a mass loss of 11.7%, which actually represent the β-cyclodextrin decomposition. In crude Euphorbia extract complexes T5 / β-CD case, the mass loss was corresponding probably to the encapsulated bioactive decomplexing phase of Euphorbia extracts’ compounds. A similar behaviour to heating was recorded in case of crude Euphorbia extract T10 / β-CD complexes. In case of Euphorbia concentrated extracts T5 / T10 - β-CD complexes, the loss can be translated as a degradation / loss of complexes’ bioactive compounds.

Key words: Euphorbia cyparissias, β-cyclodextrine, complexes, TG-DTG analysis.